Suppliers / Seven Star Pharmaceutical

Seven Star Pharmaceutical

Taiwan Updated 9 July 2026

Seven Star Pharmaceutical is an API manufacturer based in Taiwan. It holds 3 active US drug master files and 2 valid CEPs across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 21 April 2023 as NAI.

3
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 21 April 2023 NAI US FDA
  • 6 July 2018 VAI US FDA
  • 29 April 2016 VAI US FDA
  • 11 January 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
New Taipei City, Taiwan Not on file
Taiwan, Taiwan 3002769931

What they file, and where

Molecule Regulators Docs
Guaifenesin EDQM, US FDA 2
Acetylcysteine EDQM 1
Gadopentetate Dimeglumine US FDA 1
Methocarbamol US FDA 1

Also appears on these molecule pages

Acetylcysteine API Guaifenesin API Methocarbamol API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None

Questions about Seven Star Pharmaceutical

Does Seven Star Pharmaceutical hold a US DMF or a CEP?
Seven Star Pharmaceutical holds 3 active US drug master files and 2 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Seven Star Pharmaceutical FDA-registered?
One site operated by Seven Star Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Seven Star Pharmaceutical's last inspection go?
The most recent inspection on record closed on 21 April 2023 as NAI (No Action Indicated: nothing objectionable was found). 4 inspections are on file.
Where does Seven Star Pharmaceutical manufacture?
2 registered sites are on record, in Taiwan (New Taipei City and Taiwan). Every site is listed on this page with the register it came from.
What does Seven Star Pharmaceutical make?
4 molecules are on record against Seven Star Pharmaceutical, including Guaifenesin, Acetylcysteine, Gadopentetate Dimeglumine and Methocarbamol. Each links through to that molecule's full manufacturer list.
Where does Seven Star Pharmaceutical file?
Filings are on record with MINSA (CR), 1 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Seven Star Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 21 April 2023.

Comparable suppliers

Zhejiang Haizhou Pharmaceutical shares 3 molecules Granules India shares 2 molecules Delta Synthetic shares 2 molecules Synthokem Labs shares 2 molecules Imexpharm shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability